Examkin

Question

Difficulty: Very hardPulmonary and Critical Care

A 42-year-old woman presents to the clinic with progressively worsening exertional dyspnea and fatigue over the past 6 months. She has no significant past medical history and takes no medications. Physical examination reveals a prominent jugular venous a-wave, a loud pulmonic component of the second heart sound (P2), a right ventricular heave, and trace bilateral pedal edema. Her lungs are clear to auscultation. Pulmonary function testing demonstrates normal spirometry with an isolated reduction in the diffusing capacity of the lungs for carbon monoxide (DLCO). Arrange the following diagnostic and therapeutic steps in the most appropriate chronological sequence for evaluating and managing this patient's condition.

  1. 1Perform transthoracic echocardiography
  2. 2Perform a ventilation-perfusion (V/Q) scan
  3. 3Perform right heart catheterization
  4. 4Perform acute vasoreactivity testing with inhaled nitric oxide
  5. 5Initiate therapy with a high-dose oral calcium channel blocker

Answer

The correct sequence begins with echocardiography, followed by a V/Q scan, right heart catheterization, vasoreactivity testing, and finally initiation of a calcium channel blocker.
The diagnostic algorithm for pulmonary hypertension (PH) begins with suspected clinical signs such as a loud P2 and right ventricular heave, along with isolated reduced DLCO. Transthoracic echocardiography is the initial screening test to estimate pulmonary artery pressures and evaluate for Group 2 (left heart) disease. Once Group 2 and Group 3 (lung parenchymal) diseases are excluded, a V/Q scan is required to screen for Group 4 (chronic thromboembolic PH), which has a distinct surgical cure and requires specialized diagnostic imaging during subsequent catheterization. Right heart catheterization is then performed to definitively confirm pre-capillary PAH (Group 1). During catheterization, acute vasoreactivity testing (using nitric oxide, epoprostenol, or adenosine) identifies a small subset of vasoreactive patients. Only these specific patients should be treated with high-dose calcium channel blockers.

Step-by-Step Solution

1
Perform transthoracic echocardiography
Estimates pulmonary pressures and rules out left heart disease.
Initial screening test of choice for suspected pulmonary hypertension.
2
Perform a ventilation-perfusion (V/Q) scan
Screens for chronic thromboembolic pulmonary hypertension (CTEPH).
Guidelines mandate V/Q scanning to rule out Group 4 pulmonary hypertension before invasive testing.
3
Perform right heart catheterization
Confirms the diagnosis of pulmonary arterial hypertension (PAH).
Gold standard required to directly measure hemodynamics and definitively diagnose pre-capillary pulmonary hypertension.
4
Perform acute vasoreactivity testing with inhaled nitric oxide
Assesses the pulmonary vasculature's ability to dilate.
Performed during the right heart catheterization to identify patients with idiopathic PAH who will respond to calcium channel blockers.
5
Initiate therapy with a high-dose oral calcium channel blocker
Reduces pulmonary pressures and improves symptoms.
The targeted first-line medical therapy exclusively for patients who demonstrate a positive acute vasoreactivity test.

Key Concept

The diagnostic and therapeutic algorithm for pulmonary arterial hypertension.
Estimated Time:2m 0s
Rate this question

Topics

Pulmonary and Critical Care

More questions from this topic